Clinical lung transplantation from uncontrolled non-heart-beating donors revisited

J Heart Lung Transplant. 2012 Apr;31(4):349-53. doi: 10.1016/j.healun.2011.12.007. Epub 2012 Feb 3.


Background: The aim of our study is to review and update the long-term results from our previously published series of lung transplantation in uncontrolled non-heart-beating donors (NHBDs).

Methods: A prospective collection of data was undertaken from all lung transplants performed among uncontrolled NHBDs between 2002 and December 2009. The statistical analysis was performed using SPSS software and survival was estimated using the Kaplan-Meier method.

Results: Twenty-nine lung transplants were performed. Mean total ischemic times for the first and second lung were 575 minutes (SD 115.6) and 701 minutes (SD 111.3), respectively. Primary graft dysfunction (PGD) G1, G2 and G3 occurred in 5 cases (17%), 5 cases (17%) and 11 cases (38%), respectively. Overall hospital mortality rate was 17% (5 patients). Statistical analysis revealed a statistically significant association of mortality with ischemic times and with PGD. In terms of overall survival, 3-month, 1-year, 2-year and 5-year survival rates were 78%, 68%, 57% and 51%, respectively, and the conditional survival rates in those who survived the first 3 months were 86%, 72% and 65%, respectively. The cumulative incidence of bronchiolitis obliterans syndrome (BOS) was 11%, 35% and 45% at 1, 3 and 5 years, respectively.

Conclusions: Lung transplantation from uncontrolled non-heart-beating donors shows acceptable results for both mid- and long-term survival and BOS; however, the higher rates of PGD and its impact on early mortality must make us more demanding with respect to the acceptance criteria and methods of evaluation used with these donors.

MeSH terms

  • Adult
  • Bronchiectasis / mortality
  • Bronchiectasis / surgery
  • Emphysema / mortality
  • Emphysema / surgery
  • Female
  • Graft Survival*
  • Heart Arrest*
  • Humans
  • Kaplan-Meier Estimate
  • Lung Transplantation / standards*
  • Male
  • Middle Aged
  • Prevalence
  • Primary Graft Dysfunction / epidemiology*
  • Prospective Studies
  • Pulmonary Fibrosis / mortality
  • Pulmonary Fibrosis / surgery
  • Retrospective Studies
  • Survival Rate
  • Tissue Donors*
  • Treatment Outcome